Friday, July 10, 2026

pharma · Schizophrenia · Alzheimer's Disease Psychosis · ACAD

Acadia Pharmaceuticals

Acadia Pharmaceuticals is a pharma organization headquartered in Indianapolis, USA. It trades on NYSE under ticker ACAD. Primary therapeutic focus areas include Schizophrenia, Alzheimer's Disease Psychosis, Parkinson Dis

Indianapolis, USA HQ
17 Employees
Public company Type
ACAD · NYSE Ticker
Company details
Clinical program

Placebo

Phase 2 · small molecule · Anxiety

Placebo for Anxiety is a Phase 2 program (small_molecule) at Acadia Pharmaceuticals B.V. with 1 ClinicalTrials.gov record(s).

Internal code POTTERHUNTER_PROBIOTICS_2013

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Acadia Pharmaceuticals B.V.
Phase
Phase 2
Modality
small_molecule
Indication
Anxiety
Status
active
Trials
1